I would like to start a regular segment where I explain the latest findings for therapists!For our momentous first ...

A conductance-based computer model of the Parkinsonian brain circuit shows that deep brain stimulation and rhythmic visual ...

On October 7, 2026, Cerevance announced the top-line results of the Phase 3 ARISE trial for the investigational Parkinson's ...

Researchers developed a probiotic-inspired drug delivery system targeting the gut–brain axis. In Parkinson’s mouse models, it ...

The novel GPR6 inhibitor met its primary endpoint in the phase 3 ARISE trial, achieving a statistically significant reduction in daily OFF time and demonstrating non-dopaminergic motor and ...

Biochemical and animal studies suggest that cocoa-derived theobromine can affect monoamine oxidase, adenosine and neuronal ...

From Parkinson’s disease to palliative care, music therapy is showing benefits across 10 clinical settings, though the ...

A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key ...

Doctors initially told the boy's parents not to worry. But they pressed for years until a rare diagnosis became clear.

Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2Statistically significant improvements in secondary endpoints of ON time without ...

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease 1 Taken once daily with or without levodopa therapy, JUVMO offers patients a differentiated ...

Insulin-like 3 (INSL3) is a peptide hormone important for regulating male reproductive physiology. INSL3 belongs to the insulin/relaxin family of peptide hormones, which are synthesized in cells as ...